GENE ONLINE|News &
Opinion
Blog

bluebird bio
Will Breakthrough Therapy Lead the Way? An Overview of the Approved Gene and Cell Therapies for 2022
2023-01-13
Bluebird’s Rare Childhood Neurodegenerative Gene Therapy Gains Accelerated Approval
2022-09-19
Bluebird Bio’s Zynteglo Becomes First FDA-Approved Gene Therapy For Beta-Thalassemia
2022-08-18
ARM 2022: Industry Briefs on Cell and Gene Therapies
2022-01-17
FDA Grants Priority Review for bluebird bio’s β-Thalassemia Gene Therapy
2021-11-23
Resilience Acquires Bluebird Bio’s Manufacturing Facility to Develop Next Gen Cell Therapies
2021-07-31
BMS, bluebird’s Multiple Myeloma Drug Becomes First BCMA Targeting CAR-T Therapy to Snag FDA Okay
2021-03-28
Bluebird Bio Temporarily Suspends Sickle Cell Trials Following Cancer Diagnosis in Two Patients
2021-02-18
BMS, bluebird bio’s Investigational BCMA CAR-T Therapy Faces Regulatory Setback
2020-05-18
LATEST
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024-04-16
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024-04-16
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
2024-04-12
Oncology’s New Drugs on the Horizon (I): Cancer Immunotherapy and Targeted Therapy
2024-04-12
Vertex Pharmaceuticals Makes $4.9 Billion Bet on Kidney Disease Treatment through Alpine Immune Acquisition
2024-04-11
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
2024-04-10
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
Scroll to Top